 Giant cell versus lymphocytic myocarditis comparison clinical features long-term outcomes BACKGROUND Giant cell myocarditis premortem little natural history addition comparative studies lymphocytic myocarditis METHODS RESULTS clinical features serial change left ventricular fraction LVEF outcomes patients myocarditis patients giant cell myocarditis group lymphocytic myocarditis group Age presentation gender distribution duration symptoms initial LVEF hemodynamics groups Ventricular tachycardia group patients group Atrioventricular block insertion common group group Left ventricular systolic function follow-up group patients LVEF group patients LVEF net change initial final LVEF significant difference evident giant cell group lymphocytic group proportion patients group transplantation versus actuarial survival years different giant cell group lymphocytic group CONCLUSION Giant cell myocarditis prevalent ventricular tachycardia pacemaker requirement likelihood adverse event cardiovascular mortality cardiac transplantation patients giant cell myocarditis lymphocytic myocarditis progressive decline left ventricular systolic function giant cell myocarditis